Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Cancer Immunotherapy Meets Oncology

In Honor of Christoph Huber
BuchGebunden
248 Seiten
Englisch
Springererschienen am07.05.20142014
This book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing.Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.mehr
Verfügbare Formate
BuchGebunden
EUR106,99
BuchKartoniert, Paperback
EUR128,39
E-BookPDF1 - PDF WatermarkE-Book
EUR96,29

Produkt

KlappentextThis book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing.Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
Zusammenfassung
Provides a comprehensive update on the state of the art in cancer immunology

Describes the most promising therapeutic concepts, with coverage of combination therapies and personalized medicine

Discusses the role of biomarkers in guiding the clinical development of new treatment approaches
Details
ISBN/GTIN978-3-319-05103-1
ProduktartBuch
EinbandartGebunden
Verlag
Erscheinungsjahr2014
Erscheinungsdatum07.05.2014
Auflage2014
Seiten248 Seiten
SpracheEnglisch
Gewicht746 g
IllustrationenIX, 248 p. 19 illus., 18 illus. in color.
Artikel-Nr.32104747
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
Immunological and Regulatory Framework for Immuno-Oncology: From Basic Immunology to New Therapies for Patients.- How T cells single out tumor cells: 'and that has made all the difference'.- Tregs and Immune Inhibition.- Regulatory Landscape for Cancer Immunotherapy.- Immunoguiding.- Onco-Immunology Framework and Immunomodulatory Antibodies.- Immunotherapies: Peptide-based Vaccines and HPV Malignancies.- Dendritic cell based cancer vaccines.- RNA Vaccines and Personalized Medicine Approaches.-Antibody Therapy in Oncology.- Engineered Antibodies to Engage Immune Cells to the Tumor.- TCRs and TCR Therapy.- CAR Therapy.- Cancer Entities: Melanoma.- Prostate Cancer/Sipuleucel and RNA Vaccines.- Recent advances in the immunotherapy of renal cell cancer and other solid tumors.- Gastric Cancer.- NSCLC.- Breaking tolerance by allogeneic lymphocyte therapy.- Biomarkers: Exploring Immunogenic Cell Death for Patient Benefit.- Circulating Tumor Cells.- Genomics Meets Oncology.- Featured Chapters: Oncolytic Viruses.- Pharma View on Immunotherapy.- Final Remarks.mehr